# virtual_clinical_trial_agent

todo: 
- define the loop of validation / expiramentation (done)
>> find way to enter the agentic loop (done)
note: once the agent is written + validated in 1 run, make a /contextualized with some changes to work in the env correctly (full source code + IDs + how-to build on top of the DB)

>> use Claude to apply judgement; don't do it programmatically. Go trial by trial, run-by-run.

Cases:

5 RCTs that are usually feasible on an imaging/contrast cohort
1) PREDICT (2008, CT setting; CKD + diabetes)

Design: Randomized, double-blind; CT with IV iodinated contrast

Compare: iopamidol 370 (low-osmolar) vs iodixanol 320 (iso-osmolar)

Endpoint: CIN = ≥25% creatinine rise at 48–72h

Headline conclusion: No significant difference in CIN incidence between agents.

Why it’s hackathon-friendly: pure CT + labs; no need for inpatient med admin data.

2) Barrett et al. (2006, CE-MDCT; CKD)

Design: Multicenter, double-blind RCT; contrast-enhanced MDCT

Compare: iopamidol-370 vs iodixanol-320

Endpoint: CIN = ≥0.5 mg/dL and/or ≥25% creatinine rise at ~48–72h

Headline conclusion: CIN rates were low and not meaningfully different between groups (trial reports essentially comparable renal outcomes).

Why it fits your cohort: this is literally “CT + contrast + creatinine window.”

3) CARE (2007; CKD ± diabetes; cardiac angiography/PCI)

Design: Multicenter, randomized, double-blind

Compare: iopamidol vs iodixanol (intra-arterial)

Endpoint: primary = ≥0.5 mg/dL creatinine rise (2–5 days) (+ other CIN defs)

Headline conclusion: CIN rate not statistically different between agents; any true difference likely small.

Feasibility note: Works if your 77k cohort includes angiography/PCI (not just CT/MRI).

4) VALOR (2008; CKD; coronary angiography)

Design: Prospective, double-blind RCT

Compare: iodixanol vs ioversol

Endpoint: CIN = >0.5 mg/dL creatinine rise within 72h + mean peak % change

Headline conclusion: No significant overall difference in CIN incidence; some diabetic-subgroup signal on mean peak % change.

Feasibility note: Again needs enough coronary angiography volume.

5) NEPHRIC (2003; high-risk diabetes + CKD; coronary/aortofemoral angiography)

Design: Randomized trial in very high-risk patients

Compare: iodixanol vs iohexol

Endpoint: creatinine change + CIN incidence (e.g., ≥0.5 mg/dL rise)

Headline conclusion: Iodixanol showed substantially lower CIN vs iohexol in this high-risk population.

Why it’s valuable for your demo: it’s a “positive effect” benchmark (not just null results), so your vRCT can show it replicates directionality across trials.

1) PREDICT (CT; CKD + diabetes; iopamidol vs iodixanol)

Regulatory question (I):
In patients with diabetes + chronic kidney disease undergoing contrast-enhanced CT, does iodixanol 320 (iso-osmolar) reduce contrast-induced nephropathy (CIN) risk vs iopamidol 370 (low-osmolar)?

Regulatory conclusion (O):
No demonstrated renal-safety advantage: CIN incidence was not significantly different between iodixanol and iopamidol in this setting.

2) Barrett et al. 2006 (CE-MDCT; CKD; iopamidol vs iodixanol)

Regulatory question (I):
In CKD patients undergoing contrast-enhanced multidetector CT, does iodixanol 320 reduce CIN vs iopamidol 370?

Regulatory conclusion (O):
No demonstrated difference: CIN rates were similarly low with iodixanol vs iopamidol for CE-MDCT in the studied risk population.

3) CARE (cardiac angiography/PCI; CKD ± diabetes; iopamidol vs iodixanol)

Regulatory question (I):
In high-risk CKD patients (with or without diabetes) undergoing intra-arterial contrast for cardiac angiography/PCI, does iodixanol reduce CIN vs iopamidol?

Regulatory conclusion (O):
No clinically meaningful renal-safety advantage: CIN rates (across multiple CIN endpoints) were not statistically different; any true difference was likely small and not clinically significant.

4) VALOR (coronary angiography; CKD; iodixanol vs ioversol)

Regulatory question (I):
In CKD patients undergoing coronary angiography, does iodixanol reduce nephrotoxicity/CIN vs ioversol (low-osmolar)?

Regulatory conclusion (O):
Overall no significant difference in nephrotoxicity between iodixanol and ioversol; secondary signal in diabetic subgroup where a mean peak creatinine-change metric (MPPC) was lower with iodixanol.

5) NEPHRIC (high-risk diabetic nephropathy; iodixanol vs iohexol)

Regulatory question (I):
In very high-risk patients (notably diabetes + renal impairment) undergoing angiography, does iodixanol (iso-osmolar) reduce contrast-induced nephropathy/nephrotoxicity vs iohexol (low-osmolar)?

Regulatory conclusion (O):
Yes—renal safety advantage suggested: contrast-medium–induced nephropathy was less likely with iodixanol than with iohexol in this high-risk setting.